Medytox Faces Botulinum Approval Cancellation Over Data Issues
But Korean Firm Pushes Back
Executive Summary
Leading South Korean botulinum toxin company Medytox is facing substantial business risk as its Meditoxin product is suspended amid test result manipulation investigations.
You may also be interested in...
Korea Botox Rivalry To Intensify After Meditoxin Measures
As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.
Medytox, Daewoong’s Botox Strain Dispute Set To Simmer Until Commission Decision
The ongoing battle between Korea's Medytox and Daewoong Pharm over the source of the botulinum toxin strain in Daewoong’s product looks set to rumble on until a trade commission unveils the results of its probe next year.
Korean Industry Demands Bold Support Amid US Policy Moves
As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.